The Muscle-Loss Problem Nobody Sells You: Why “Peptides for Fat Loss” Is the Wrong Frame and Body Composition Is the Real Target

This article is for general informational and educational purposes only and is not medical advice. It discusses FDA-approved prescription medications and unauthorized research compounds; the latter are not approved by Health Canada or the FDA to diagnose, treat, cure, or prevent any disease, and you should consult a qualified healthcare professional before pursuing any treatment for weight, muscle, or metabolic health.

There is a number on the scale, and then there is what your body is actually made of, and almost every “peptides for fat loss” article quietly conflates the two. The promise is weight loss. The thing most people actually want is fat loss with their muscle intact, which is a different and harder goal. This distinction is not academic. When researchers put people who lost weight on GLP-1 medications into DEXA scanners, they found that a substantial share of what disappeared was not fat but lean tissue. In the STEP-1 semaglutide trial, lean mass fell by roughly 9.7 percent even as fat mass fell faster at about 19.3 percent, and across the GLP-1 literature, lean tissue has accounted for somewhere around a quarter to 40 percent of total weight lost depending on the analysis. That is the part the marketing leaves out, and it is precisely the part that matters most for how you look, how strong you are, and how well your metabolism works afterward. Into this gap steps an entire industry selling “muscle-preservation stacks,” combinations of growth-hormone-secretagogue peptides like CJC-1295, Ipamorelin, MK-677, Tesamorelin, and AOD-9604, marketed as the way to lose fat while keeping or even building muscle. The pitch is seductive because it names a real problem. The trouble is that the evidence those specific stacks solve it is thin, while the interventions that demonstrably do preserve muscle during weight loss are unglamorous and rarely the thing being sold: adequate protein and resistance training. This article reframes the entire question around body composition rather than scale weight. It covers what the popular pages cover, the peptides marketed for fat loss and recomposition, but it builds the layer they skip: what weight loss actually does to muscle, why the grey-market “preservation” stacks are not the proven answer, what the real evidence supports, and how a Canadian reader should think about all of it.

Why body composition, not weight, is the question that actually matters

If two people each lose twenty pounds and one loses it almost entirely as fat while the other loses a third of it as muscle, they have had completely different outcomes despite identical movement on the scale. Muscle is metabolically active tissue; losing it lowers resting energy expenditure, which makes weight regain easier and is part of why aggressive dieting so often rebounds. Muscle also underpins strength, balance, bone support, glucose disposal, and, with age, independence. So “did I lose weight” is the wrong scorecard. “What did I lose, and what did I keep” is the right one.

This reframing exposes why “peptides for fat loss” is a slightly misleading phrase. The goal worth pursuing is not maximal scale loss; it is maximal fat loss with minimal lean loss, sometimes called body recomposition. Once you adopt that lens, the questions change. It is no longer “which peptide burns the most fat” but “which approach removes fat while protecting muscle,” and that question has a surprising answer that has little to do with most of the compounds being marketed. Even the clinicians most enthusiastic about GLP-1 medications have begun stressing this point: weight loss that is not managed for muscle can lead to what one practice bluntly called burnout, muscle loss, rebound weight gain, and metabolic harm. The number on the scale is a poor proxy for the outcome you want.

What weight loss, including GLP-1 weight loss, actually does to muscle

Here is the foundational fact the marketing rarely states plainly: all weight loss tends to include some lean mass loss. This is not unique to GLP-1 drugs; it is a feature of energy deficit itself. When you lose weight by any means, some fraction of the loss is lean tissue, and the faster and larger the loss, the more there is to be concerned about. GLP-1 medications produce large, rapid weight loss, which is exactly why the lean-mass question has become so prominent with them, not because they specially attack muscle.

The numbers are worth stating carefully because they are often exaggerated in both directions. DEXA data from the semaglutide STEP-1 trial showed lean mass declining about 9.7 percent against fat mass declining about 19.3 percent, meaning fat loss predominated and the proportion of the body that was lean actually rose by a few percentage points. At the same time, expressed as a share of total weight lost, lean tissue commonly represents roughly 25 to 40 percent, and some imaging studies have flagged meaningful core muscle volume loss even in people exercising casually. Both framings are true and describe different things: relative to body size, composition can improve, while in absolute terms real muscle is still being lost. A peer-reviewed review of GLP-1 agonists and exercise, available through the open-access analysis of GLP-1 therapy and lifestyle prioritization indexed in PubMed Central, lays out this trade-off and concludes that the lean-mass loss has potential long-term functional implications if it is not counteracted by resistance exercise. Crucially, the same research lines suggest this loss is largely adaptive to weight loss rather than a unique toxic drug effect, which is why the solution is about how you lose weight, not simply which drug you use.

What an honest “peptides for fat loss” guide has to address

A guide that takes body composition seriously has to do several things the typical recomposition page does not. It has to state what weight loss does to muscle honestly, with real numbers. It has to evaluate, individually and skeptically, the grey-market peptides sold specifically as muscle-preservation tools, rather than assuming the stack works because the goal is real. It has to surface the interventions that actually have evidence for preserving lean mass. It has to address the emerging pharmacological frontier honestly, including approved drugs and genuine investigational muscle-preservation agents, without conflating them with research-grade powders. And it has to lay out the Canadian regulatory reality. The popular pages name the muscle-preservation goal and then immediately sell a stack; the honest version sits with the question of whether those stacks are actually the answer, and mostly finds that the boring interventions outperform them on evidence.

The grey-market “muscle-preservation stacks”: named problem, unproven solution

The recomposition marketplace is built on a clever move. It correctly identifies that losing muscle during fat loss is bad, then offers growth-hormone-secretagogue peptides as the fix, on the logic that raising growth hormone and IGF-1 should protect or build muscle. The compounds typically include CJC-1295 and Ipamorelin (often stacked together), Sermorelin, the oral secretagogue MK-677, Tesamorelin, and frequently AOD-9604, sometimes bundled into “body recomposition formulas.”

The mechanism is plausible, and that plausibility is doing most of the persuasive work. But plausibility is not evidence, and the evidence that these specific compounds meaningfully preserve lean mass during a fat-loss phase in ordinary adults is weak. They can raise growth hormone and IGF-1, but controlled human trials demonstrating that this translates into better body composition outcomes, more muscle retained per pound of fat lost, are largely absent for these peptides as marketed. AOD-9604 is the starkest case: it is frequently included in fat-loss and recomposition blends, yet its own pivotal 24-week, 536-subject obesity trial failed to beat placebo on weight loss, development was terminated in 2007, and pooled analysis across roughly 900 participants found no clinically significant effect. A compound that failed to produce fat loss is being sold as part of a fat-loss-and-muscle stack. Tesamorelin, by contrast, has genuine evidence but only for a narrow indication, reducing visceral fat in HIV-associated lipodystrophy, which does not establish it as a general recomposition tool. The pattern across the stack is consistent: real mechanism, real marketing, thin or absent outcome evidence for the specific muscle-preservation claim, and in some cases evidence pointing the other way.

What actually preserves muscle during fat loss

The genuinely well-supported answer is almost anticlimactic, which is probably why it sells poorly: adequate protein intake and resistance training. The evidence here is consistent and, unlike the stack claims, directly measured.

On protein, an Endocrine Society study presented in 2025 found that among people losing weight on semaglutide, eating less protein, along with being older or female, predicted greater muscle loss, and that losing more muscle was linked to less improvement in blood sugar. The practical recommendations that emerge from the broader literature cluster around 1.2 to 2 grams of protein per kilogram of body weight daily during weight loss, higher than typical sedentary intake. On training, the signal is even clearer: resistance exercise provides the stimulus that tells the body to keep muscle while in a deficit. A case series and a larger 2025 cohort found that people combining GLP-1 medications with structured resistance training and individualized higher protein intake preserved substantially more muscle, in some reports two to three times more, with some individuals even gaining lean mass while losing 13 to 33 percent of body weight. One analysis of a roughly 200-adult program reported about 13 percent body-weight loss with only about 3 percent muscle loss when resistance training and protein were emphasized.

The contrast with the stacks is the whole point. The interventions with real, measured evidence for preserving muscle during fat loss are protein and lifting, available to anyone, no injection required. The compounds being sold as the muscle-preservation solution are the ones with the thinnest evidence for that specific job. A reader optimizing for body composition who spends on a recomposition peptide stack while neglecting protein and resistance training has almost certainly inverted the priority order. General, non-commercial guidance on protein needs and strength activity is available through the weight-management resources published by the U.S. National Institute of Diabetes and Digestive and Kidney Diseases, a better starting point than any stack vendor’s protocol page.

The legitimate pharmacological frontier, kept separate from the grey market

Honesty requires noting that real pharmacological muscle-preservation science is advancing, and it should not be confused with the grey-market stacks. The clearest example is the investigational combination of bimagrumab, an antibody that acts on muscle, with semaglutide; the BELIEVE study presented at a major diabetes meeting examined whether adding such an agent could enhance fat loss while preserving lean mass. There is also active development of better body-composition measurement tools, including continuous protein sensors for tracking muscle during therapy. This is the difference that matters: these are studied agents progressing through proper trials and scientific scrutiny, a categorically different thing from a research-grade GH-secretagogue powder sold online with a recomposition label. The existence of a legitimate frontier does not validate the grey market; if anything, it underscores how much the marketed stacks are running ahead of their evidence, since the genuine muscle-preservation pharmacology is still being established in trials rather than sold as a finished solution.

A scenario: problem, cause, solution, outcome

The problem. Take someone who started a GLP-1, is thrilled with the scale dropping, but has noticed they look “softer” and feel weaker, and is now considering adding a CJC-1295 and Ipamorelin stack from an online vendor to “keep their muscle.”

The cause. They optimized for scale weight, not composition, and a meaningful share of their loss was lean tissue, which is the normal consequence of rapid weight loss without a muscle-preservation strategy. The recomposition marketing then offered a peptide stack as the fix, matching their fear to a product, even though the stack’s evidence for actually preserving muscle is thin and one of its common ingredients failed its own trials.

The solution. They reorient around composition. Before adding any compound, they raise protein toward the 1.2 to 2 grams per kilogram range and start resistance training two to three times a week, the interventions with real measured evidence for preserving lean mass on a GLP-1. They treat the grey-market stack skeptically, recognizing the mechanism is plausible but the outcome evidence for that specific use is weak, and they discuss muscle preservation with the clinician managing their GLP-1.

The outcome. Their composition trajectory improves through the changes that are actually evidence-based, and the muscle loss that prompted the panic is addressed at its real cause, deficit without a muscle-preservation stimulus, rather than papered over with an unproven injectable. If genuine pharmacological muscle-preservation options become appropriately available and supported by evidence, that becomes a clinician-guided decision rather than a fear-driven online purchase.

The Canadian regulatory reality

The legal dimension sorts these options sharply for a Canadian reader. The approved GLP-1 and GLP-1/GIP medications are prescription drugs, dispensed through licensed pharmacies under medical supervision and carrying a Drug Identification Number; that is also the setting in which muscle-preservation can actually be managed, through monitored protein and training guidance. The grey-market recomposition peptides, the GH secretagogues, MK-677, AOD-9604, and unauthorized “research” versions of any of these, fall under Health Canada’s warning against unauthorized injectable peptides. Health Canada has stated these products are not assessed for safety, efficacy, or quality, that “For Research Use Only” labeling does not make them legal for human use, and it works with the Canada Border Services Agency to intercept unauthorized shipments.

So the very stacks marketed as the sophisticated body-composition solution are, in their unauthorized forms, both the lower-evidence option for muscle preservation and the one operating against the regulator’s position. Canadians weighing options have started comparing how research-compound retailers such as NØX Peptides present these products explicitly as research materials rather than as proven body-composition therapeutics, which is the framing consistent with their actual status. For readers curious how such compounds are categorized for research, a catalog’s organization, for instance the muscle-growth grouping within a Canadian research-peptide catalog, reflects marketed research interest rather than demonstrated muscle-preservation efficacy, and the evidence and legal cautions above apply regardless of where a research compound is obtained.

How to evaluate whether your peptides-for-fat-loss decision is sound

Run this diagnostic, which keeps the focus on composition rather than scale weight.

• Am I optimizing for scale weight or for fat loss with muscle preserved? The second is the goal that actually determines your outcome.
• Do I understand that all rapid weight loss, including on GLP-1s, costs some lean mass? It is a feature of energy deficit, not a unique drug toxicity.
• Have I prioritized protein and resistance training before any compound? These are the interventions with real measured evidence for preserving muscle.
• Am I treating a plausible mechanism as proof a stack works? Raising growth hormone is a mechanism, not demonstrated body-composition benefit.
• Does my “recomp” stack contain compounds that failed their own trials? AOD-9604, common in these blends, did not beat placebo for fat loss.
• Am I confusing a narrow approval with general efficacy? Tesamorelin’s evidence is for HIV-lipodystrophy visceral fat, not general recomposition.
• Is muscle preservation being managed by a clinician alongside any GLP-1? Monitoring protein, training, and lean mass is part of doing this well.
• What is the legal status in Canada of the specific compound I’m considering? Approved GLP-1s are prescription drugs; recomposition stacks are often unauthorized.

Video: “What Do Peptides Actually Do?”

For a broad orientation to peptides before narrowing to any specific compound or stack, this Diary Of A CEO conversation with Dr. Alex Tatem is a useful companion to the body-composition argument above. Its central discipline, “start with the problem, not the solution,” is exactly the move this article asks of a reader: define the real goal, fat loss with muscle preserved, before reaching for a product, rather than letting a marketed stack define the goal for you.

Watching a general framework like this alongside the compound-specific and evidence-specific points above helps keep the focus on the outcome that matters rather than on whichever stack is being promoted.

Frequently Asked Questions

Do GLP-1 medications like semaglutide cause muscle loss?

They do not directly attack muscle, but the large, rapid weight loss they produce is accompanied by some lean mass loss, which is a feature of energy deficit rather than a unique drug toxicity. DEXA data from the STEP-1 semaglutide trial showed lean mass falling about 9.7 percent while fat mass fell faster at about 19.3 percent, and across the literature lean tissue can account for roughly 25 to 40 percent of total weight lost. The practical implication is that muscle loss is real and worth managing, but it is largely addressable through how you lose the weight, specifically adequate protein and resistance training, rather than being an unavoidable consequence of the medication itself.

Do peptide “stacks” like CJC-1295 and Ipamorelin actually preserve muscle during fat loss?

The mechanism is plausible, since these compounds can raise growth hormone and IGF-1, but the evidence that they meaningfully preserve lean mass during a fat-loss phase in ordinary adults is thin, with controlled body-composition outcome trials largely absent for these peptides as marketed. The marketing correctly identifies a real problem, muscle loss during weight loss, then offers a solution whose specific benefit for that job is not well established. Some compounds commonly included in these stacks, such as AOD-9604, actually failed their own trials, so plausibility should not be mistaken for demonstrated effect.

What actually preserves muscle while losing fat?

The best-supported interventions are adequate protein intake and resistance training, and the evidence for them is directly measured rather than merely mechanistic. Studies suggest protein in the range of roughly 1.2 to 2 grams per kilogram of body weight daily during weight loss, and research found that people combining GLP-1 medications with structured resistance training and higher protein preserved substantially more muscle, in some cases two to three times more, with some individuals gaining lean mass while losing significant body weight. An Endocrine Society study also found that eating less protein predicted greater muscle loss on semaglutide. These approaches are available to anyone and require no injectable compound.

Why is body composition more important than the number on the scale?

Because two people who lose the same weight can have completely different outcomes depending on whether they lost mostly fat or a significant amount of muscle. Muscle is metabolically active and supports strength, balance, bone, glucose handling, and long-term independence, so losing it lowers resting energy expenditure and makes weight regain easier, which is part of why aggressive dieting often rebounds. Optimizing for fat loss with muscle preserved, sometimes called body recomposition, produces a better functional and metabolic result than maximizing scale loss alone, which is why the framing of the goal matters as much as the method.

Is AOD-9604 a good choice for fat loss and recomposition?

The human evidence does not support it. AOD-9604 is a growth hormone fragment marketed as a direct fat-burner, but its pivotal 24-week placebo-controlled trial in 536 subjects failed to beat placebo on weight loss, development was terminated in 2007, and a pooled analysis of roughly 900 participants found no clinically significant difference from placebo. Despite this, it is frequently included in recomposition blends, which means a compound that did not produce fat loss in trials is being sold as part of a fat-loss-and-muscle product. It is well tolerated but not an effective fat-loss agent at meaningful magnitudes, so its inclusion in a stack is not evidence-based.

Is Tesamorelin a general body recomposition peptide?

No. Tesamorelin is a growth-hormone-releasing hormone analogue approved for a narrow indication, reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy, where it has genuine trial evidence. That approval does not establish it as a general recomposition tool for the broader population, and marketing that uses its legitimate narrow approval to imply general fat-loss-with-muscle benefits is overreaching. It illustrates the broader principle that “approved” always means approved for something specific, not a blanket endorsement for any body-composition use.

Are these fat-loss and recomposition peptides legal in Canada?

It depends on the specific compound. The approved GLP-1 and GLP-1/GIP medications are legal prescription drugs dispensed through licensed pharmacies under medical supervision and carrying a Drug Identification Number. The grey-market recomposition peptides, including GH secretagogues, MK-677, AOD-9604, and unauthorized research versions of any of these, fall under Health Canada’s warning against unauthorized injectable peptides, which states they are not assessed for safety, efficacy, or quality and that research-use labeling does not make them legal for human use. So some options are legal medications used with oversight and others are unauthorized products the regulator advises against.

Is there legitimate pharmacological research on preserving muscle during weight loss?

Yes, and it should be kept separate from the grey-market stacks. The clearest example is the investigational combination of bimagrumab, an antibody acting on muscle, with semaglutide, studied in the BELIEVE trial for whether it can enhance fat loss while preserving lean mass, alongside development of better body-composition measurement tools. These are agents progressing through proper clinical trials and scientific scrutiny, which is fundamentally different from a research-grade growth-hormone-secretagogue powder sold online with a recomposition label. The existence of this legitimate frontier does not validate the marketed stacks; it highlights that genuine muscle-preservation pharmacology is still being established rather than sold as a finished solution.

Important Disclaimers and Regulatory Notes

This article is editorial and informational only and does not constitute medical, legal, or veterinary advice. It distinguishes FDA-approved prescription peptide medications, which should be used only under the care of a licensed healthcare professional, from unauthorized research-use compounds, which are not approved by Health Canada or the FDA to diagnose, treat, cure, or prevent any disease and are not for human consumption unless explicitly labeled and approved otherwise. Statements about muscle preservation and specific compounds reflect the current state of published evidence, which for several grey-market recomposition peptides is limited, mechanistic, or in some cases negative. Health Canada generally regulates injectable peptides as prescription drugs and has warned against purchasing or using unauthorized products, including those labeled “For Research Use Only,” noting that such labeling does not confer legality. Readers should consult a qualified healthcare professional before changing diet, training, or treatment, and comply with all applicable Canadian federal and provincial laws and institutional requirements.